This Cheap Michigan Biotech Could Have Major Phase II Catalysts Coming

Published: Mar 20, 2017

Shares have traded relatively flat since the company's initial public offering.

Share price could runup into three data readouts from phase 2b trials.

Principal asset gemcabene appears to have a differentiated profile that could allow the company to carve its niche in several indications in the cardiometabolic arena.

Back to news